Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-13T14:02:29.328Z Has data issue: false hasContentIssue false
  • English
  • Français

10 Pharmacodynamics and Tolerability of Intranasally Administered Immediate-Release Amphetamine Sulfate Among Recreational Intranasal StimulantUsers

Published online by Cambridge University Press:  12 March 2019

Beatrice Setnik ,
Steve Caras ,
Terrilyn Sharpe  and
Stephen V. Faraone
Beatrice Setnik
Affiliation:
Vice President Scientific & Clinical Strategy, Early Phase, Syneos Health, Raleigh, NC, USA, and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
Steve Caras
Affiliation:
Vice President Clinical Development, Arbor Pharmaceuticals, LLC, Atlanta, GA, USA
Terrilyn Sharpe
Affiliation:
Director of Clinical Development, Arbor Pharmaceuticals, LLC, Atlanta, GA, USA
Stephen V. Faraone
Affiliation:
Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Study Objective

Despite increased nonmedical use of ADHD prescription stimulants, there are limited data to inform selection of intranasal doses for abuse-potential evaluations. This study determined a dose of amphetamine sulfate that is tolerable and distinguishable from placebo on pharmacodynamic (PD) measures.

Methods

In this randomized, double-blind, placebo-controlled, dose-escalation study, healthy, nondependent, recreational stimulant users received a single intranasal dose of amphetamine sulfate (20, 30, or 40mg ; n=6 per group) or placebo (n=2 per group). PD and safety were assessed pre-dose and ≤24hours post-dose. Drug Liking was measured using a bipolar Visual Analogue Scale (VAS; 0–100). Dose selection criteria were complete dose insufflation (≥95%); demonstration of peak Drug Liking ≥75 points, and ≥15 points greater than placebo in ≥3 participants receiving active drug; and tolerability.

Results

Peak Drug Liking criteria were met in the 20-, 30-, and 40-mg groups by 2, 0, and 6 participants, respectively. Mean (SD) peak Drug Liking was 62 (13.0), 71 (17.8), and 93 (8.7) for amphetamine sulfate versus 54 (3.5), 76 (34.6), and 51 (0) for placebo in the 20-, 30-, and 40-mg groups, respectively. Thirteen participants experienced mild AEs (n=1, 4, 6, and 1 in 20-, 30-, 40-mg, and placebo groups, respectively), there were no serious or clinically significant AEs. The most common AE was nostril burning sensation (active drug, n=7). There were no instances of an incompletely insufflateddose.

Conclusion

A 40-mg intranasal dose produced distinguishable PD effects and was well tolerated. This dose has been selected for further abuse-potential evaluations.

Funding Acknowledgements: This study was funded by Arbor Pharmaceuticals, LLC.

Type
Abstracts
Information
CNS Spectrums , Volume 24 , Issue 1 , February 2019 , pp. 178
Copyright
© Cambridge University Press 2019